Opendata, web and dolomites

SA-VOIR SIGNED

Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SA-VOIR project word cloud

Explore the words cloud of the SA-VOIR project. It provides you a very rough idea of what is the project "SA-VOIR" about.

strengthen    critical    business    upfront    halt    black    glaucoma    family    inherently    biotechnological    treatments    act    blindness    vash    milestone    normal    candidate    attract    small    manner    indicated    affinity    commercialize    aside    santen    enzyme    million    sa    implicated    followed    voir    pharmaceutical    optimization    diagnosed    inhibit    deterioration    companies    applicability    stage    subtype    broad    peripheral    parkinson    mt    house    alzheimer    components    pharmaceuticals    drugs    imminent    deal    de    plan    elucidated    irreverisble    hyperactivated    causes    assets    tunnel    start    investment    applicable    form    diseases    prominent    patients    drug    receive    guide    inhibits    seeing    dysregulation    clinical    documents    trials    inhibiting    molecule    eye    nanomolar    011    tension    total    risked    40m    proprietary    vision    size    30    people    biochemical    outline    neurodegenerative    world    payments    report    assay    licensing    pfizer    neurogenerative    disorder    newly    continued   

Project "SA-VOIR" data sheet

The following table provides information about the project.

Coordinator
MT ACT 

Organization address
address: 66 RUE DU CLAOUS
city: CAZILHAC
postcode: 34190
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MT ACT FR (CAZILHAC) coordinator 50˙000.00

Map

 Project objective

Glaucoma is the world's leading cause of irreverisble blindness, affecting 20 million people in Europe and the US. Known as the Alzheimer’s of the eye, glaucoma is a neurodegenerative disorder that causes deterioration in peripheral vision. Affected patients report ‘seeing through a black tunnel’. Treatments to halt vision loss are available however, they are only applicable for the ‘high tension glaucoma’ subtype. For those diagnosed with ‘normal tension', which comprises over 30% of glaucoma patients, no treatments are available, and vision loss is imminent. New drugs that inhibit VASH, a newly elucidated enzyme that is hyperactivated in many neurogenerative diseases, have potential to address this need.

We at MT-act are a biotechnological start-up who have identified a family of VASH-inhibiting small molecule drugs. Using an in-house proprietary biochemical assay followed by lead optimization, we have identified MT-011, which inhibits VASH with nanomolar affinity, as our lead candidate. Aside from glaucoma, VASH dysregulation is also implicated in other prominent neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Our assets therefore have an inherently broad applicability.

We aim to develop MT-011 up to the stage of Phase 1 clinical trials, upon which we aim to commercialize the drug via a licensing deal with a pharmaceutical partner. We will then receive upfront and milestone payments with a estimated total deal size of €40M. We are currently in discussion with world-leading pharmaceutical companies Pfizer and Santen Pharmaceuticals, who have already indicated interest in our drugs.

In SA-VOIR, we aim to strengthen the business case for MT-011 and to outline a detailed technical plan for its continued development. These documents will not only guide us in developing MT-011 towards Phase 1 trials in an effective and de-risked manner, it will also form critical components of a business plan that we will use to attract further investment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SA-VOIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SA-VOIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

BEMYEYES (2019)

Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More